RTX-GRT7039, Naropin® 5 mg/ml Injektionslösung
KF7039-03
Phase 3 small_molecule active
Quick answer
RTX-GRT7039, Naropin® 5 mg/ml Injektionslösung for Moderate to severe pain associated with Osteoarthritis of the knee is a Phase 3 program (small_molecule) at Gruenenthal GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Gruenenthal GmbH
- Indication
- Moderate to severe pain associated with Osteoarthritis of the knee
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active